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Tom Fitzpatrick made many protean contributions in many
diverse areas of clinical dermatology and melanobiology, and
among his lifelong interests were the pigmentary anomalies
of various single gene Mendelian disorders. He was the first
to show that the white spots of piebaldism generally lack
melanocytes (Breathnach et al, 1965; Jimbow et al, 1975),
whereas the dark spots of neurofibromatosis type 1 (NF1)
contain macromelanosomes (Jimbow et al, 1973) or, as he
called them, ‘‘melanin macroglobules’’ (Nakagawa et al,
1984; Martuza et al, 1985). These studies were all published
in the Journal, and opened the door to better understanding
of the cell biology of these two genetic diseases.
Fitz also led the way towards establishing guidelines to
assist in the clinical diagnosis of both piebaldism (Mosher
and Fitzpatrick, 1988) and NF1 (Fitzpatrick et al, 1981;
Fitzpatrick and Martuza, 1986; Mackool and Fitzpatrick,
1992). These efforts notwithstanding, a point of confusion
remains in the relationship between these two distinct
disorders. Several case reports have been published (and
several others have eventually not been published) describ-
ing patients with both piebaldism and NF1 (Chang et al,
1993; Tay, 1998; Angelo et al, 2001), which the authors
claimed represent a nonrandom, causal relationship. In fact,
none of these patients, or any of their relatives, had any of
the nonpigmentary features of NF1, such as cutaneous
neurofibromas, the sine qua non of NF1, although the
patient described by Tay (1998) reportedly had Lisch
nodules on ophthalmologic examination. Each of these
authors explicitly based their clinical diagnoses of NF1 on
the presence of two established NF1 diagnostic criteria
(National Institutes of Health Consensus Development
Conference, 1988). We suggest that proposing a causal
relationship between NF1 and piebaldism is premature,
based on the known clinical features, genetic etiology, and
molecular pathogenesis of these two distinct disorders.
First, piebaldism is an autosomal dominant disorder of
hypopigmentation, in which affected individuals present with
areas of cutaneous depigmentation, associated with a virtual
absence of melanocytes. In contrast, NF1 is an autosomal
dominant disorder of hyperpigmentation, in which affected
individuals exhibit hyperpigmented macules (cafe´-au-lait
spots), skinfold freckling, and pigmented iris hamartomas
(Lisch nodules), associated with increased numbers of
melanocytes and macromelanosomes (Nakagawa et al, 1984).
Second, the genetic bases for these two disorders are
distinct. Piebaldism results from mutations of the KIT gene
on chromosome 4q12 (Giebel and Spritz, 1991; Spritz et al,
1993; Spritz, 1994) or the SLUG (SNAI2) gene on chromo-
some 8q11 (Sa´nchez-Martı´n et al, 2003), whereas NF1
results from mutations of the NF1 gene on chromosome
17q11.2 (Viskochil et al, 1990; Wallace et al, 1990).
Third, the molecular pathogeneses of piebaldism and
NF1 represent polar opposites. Inactivating mutations or
deletions of the KIT (receptor tyrosine kinase) or SLUG (zinc
finger neural crest transcriptional factor) genes result in
decreased receptor tyrosine kinase signaling, impaired
melanoblast development, and a decrease in melanogen-
esis (Spritz, 1994, 1998). In contrast, inactivating mutations
or deletions in the NF1 gene result in hyperactivation of the
RAS proto-oncogene and enhanced receptor tyrosine
kinase signaling. In addition, studies on NF1-associated
neurofibromas have demonstrated increased KIT expres-
sion and activity (Hirota et al, 1993; Ryan et al, 1994;
Badache et al, 1998).
Lastly, recent studies on mice have suggested that NF1
inactivation would result in a partial correction of the
pigmentary abnormalities in piebaldism. Mice with an
inactivating mutation in the Kit gene exhibit severe coat
color defects, which were reversed (60%–70% correction)
when these mice were bred with mice harboring an
inactivating mutation in the Nf1 gene (Ingram et al, 2000).
These results argue that the coexistence of NF1 and KIT
mutations in humans might partially abrogate the hypopig-
mentary defects seen in piebaldism.
The finding of six or more cafe´-au-lait spots and axillary
or inguinal freckling is indeed considered sufficient to make
the diagnosis of NF1 using established diagnostic criteria
(National Institutes of Health Consensus Development
Conference, 1988; Gutmann et al, 1997). Cafe´-au-lait spots
are a common feature of piebaldism, however (Smith and
Schultz, 1955; Ansari, 1960; Gru¨pper et al, 1970; Selmano-
witz et al, 1977; Gatto et al, 1985; Ku¨ster, 1987; Spritz et al,
1993; Syrris et al, 2000), and axillary and/or inguinal
freckling, although not explicitly described, also occurs
frequently (Fig 1) (our unpublished observations; W. Ku¨ster,
personal communication). We have previously pointed out
that this has resulted in a number of patients with
piebaldism being misdiagnosed with NF1 (Spritz, 1998),
even by experts (e.g., Riccardi, 1993). In order to establish a
direct cause and effect relationship between piebaldism
and NF1, future studies will require that the mutational
status of the KIT and NF1 genes in the probands be proven
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and their relatives be examined as well to demonstrate
additional nonpigmentary features of NF1 in these indivi-
duals (e.g. neurofibromas).
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Figure 1
A patient with autosomal dominant piebaldism due to a KIT gene
mutation. This patient is heterozygous for an R791G missense
substitution in the kinase domain of the KIT polypeptide (Spritz et al,
1993). Note cafe´-au-lait spots and axillary freckling. Her mother is
similarly affected (as are many other relatives), but neither have any
nonpigmentary features of NF1.
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